Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q30154
UPID:
DRB5_HUMAN
Alternative names:
DR beta-5; DR2-beta-2; Dw2; MHC class II antigen DRB5
Alternative UPACC:
Q30154; B2RBV6; C7C4X3; O00157; O00283; O46700; Q29703; Q29787; Q29788; Q30126; Q30150; Q30199; Q6SJR2; Q7M2H9; Q8HWS7; Q8WLR5; Q9MY54; Q9XRX6
Background:
HLA class II histocompatibility antigen, DR beta 5 chain, known as DR beta-5, DR2-beta-2, Dw2, and MHC class II antigen DRB5, plays a crucial role in the immune system. It binds peptides from antigens processed via the endocytic route, presenting them on APC surfaces for CD4 T-cell recognition. This process is vital for the exogenous antigen presentation pathway, involving peptide generation through lysosomal degradation. MHC class II molecules also interact with CD74 in the ER, forming a complex that undergoes processing to present antigens effectively.
Therapeutic significance:
Understanding the role of HLA class II histocompatibility antigen, DR beta 5 chain, could open doors to potential therapeutic strategies.